Abstract
Tissue biopsy alone is diagnostic in less than 10% of cases of metastatic bone disease with an unknown primary tumor. Accordingly, to delineate the neoplastic process in cases of metastatic bone disease, where the primary tumor cannot be determined with conventional modalities, new tools are attractive. Complementary deoxyribonucleic acid microarrays may be such a tool. Verification and validation of this technology for analysis of specimens ex vivo is mandatory if it is to be used to analyze the complexity of heterogenous biologic tissues. To convey the issues involved in the clinical application of cDNA microarray analysis of tumor specimens ex vivo, a set of experiments analyzing surgically resected human specimens is presented. The specific aims of the analysis were to assess cDNA microarray reproducibility of serial tissue preparations of tumor samples and to confirm that heterogeneity within a given clinical tumor specimen does not preclude this technique as a tool to discern tumor types. Complementary deoxyribonucleic microarray analysis, as it applies to heterogeneous clinical tumor samples in limited numbers, based on preliminary data, seems to be an appropriate but still experimental method for distinguishing tumor types.
| Original language | English (US) |
|---|---|
| Journal | Clinical Orthopaedics and Related Research |
| Issue number | 415 SUPPL. |
| DOIs | |
| State | Published - Jan 1 2003 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Orthopedics and Sports Medicine
Cite this
Validation of cDNA Microarray Analysis to Distinguish Tumor Type Ex Vivo. / Randall, R; Wade, Mark; Albritton, Karen H.; Coffin, Cheryl M.; Joyner, David E.
In: Clinical Orthopaedics and Related Research, No. 415 SUPPL., 01.01.2003.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Validation of cDNA Microarray Analysis to Distinguish Tumor Type Ex Vivo
AU - Randall, R
AU - Wade, Mark
AU - Albritton, Karen H.
AU - Coffin, Cheryl M.
AU - Joyner, David E.
PY - 2003/1/1
Y1 - 2003/1/1
N2 - Tissue biopsy alone is diagnostic in less than 10% of cases of metastatic bone disease with an unknown primary tumor. Accordingly, to delineate the neoplastic process in cases of metastatic bone disease, where the primary tumor cannot be determined with conventional modalities, new tools are attractive. Complementary deoxyribonucleic acid microarrays may be such a tool. Verification and validation of this technology for analysis of specimens ex vivo is mandatory if it is to be used to analyze the complexity of heterogenous biologic tissues. To convey the issues involved in the clinical application of cDNA microarray analysis of tumor specimens ex vivo, a set of experiments analyzing surgically resected human specimens is presented. The specific aims of the analysis were to assess cDNA microarray reproducibility of serial tissue preparations of tumor samples and to confirm that heterogeneity within a given clinical tumor specimen does not preclude this technique as a tool to discern tumor types. Complementary deoxyribonucleic microarray analysis, as it applies to heterogeneous clinical tumor samples in limited numbers, based on preliminary data, seems to be an appropriate but still experimental method for distinguishing tumor types.
AB - Tissue biopsy alone is diagnostic in less than 10% of cases of metastatic bone disease with an unknown primary tumor. Accordingly, to delineate the neoplastic process in cases of metastatic bone disease, where the primary tumor cannot be determined with conventional modalities, new tools are attractive. Complementary deoxyribonucleic acid microarrays may be such a tool. Verification and validation of this technology for analysis of specimens ex vivo is mandatory if it is to be used to analyze the complexity of heterogenous biologic tissues. To convey the issues involved in the clinical application of cDNA microarray analysis of tumor specimens ex vivo, a set of experiments analyzing surgically resected human specimens is presented. The specific aims of the analysis were to assess cDNA microarray reproducibility of serial tissue preparations of tumor samples and to confirm that heterogeneity within a given clinical tumor specimen does not preclude this technique as a tool to discern tumor types. Complementary deoxyribonucleic microarray analysis, as it applies to heterogeneous clinical tumor samples in limited numbers, based on preliminary data, seems to be an appropriate but still experimental method for distinguishing tumor types.
UR - http://www.scopus.com/inward/record.url?scp=0142157079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0142157079&partnerID=8YFLogxK
U2 - 10.1097/01.blo0000093060.96273.db
DO - 10.1097/01.blo0000093060.96273.db
M3 - Article
C2 - 14600600
AN - SCOPUS:0142157079
JO - Clinical Orthopaedics and Related Research
JF - Clinical Orthopaedics and Related Research
SN - 0009-921X
IS - 415 SUPPL.
ER -